Merck & Co., Inc. (NYSE:MRK – Get Rating) –  Jefferies Financial Group cut their Q1 2023 EPS estimates for shares of Merck & Co., Inc.  in a research report issued on  Wednesday, April 12th. Jefferies Financial Group analyst A. Tewari now forecasts that the company will post earnings of $1.34 per share for the quarter, down from their previous estimate of $1.66. Jefferies Financial Group currently  has a “Buy” rating and a $125.00 target price on the stock. The consensus estimate for Merck & Co., Inc.’s current full-year earnings is $6.88 per share.

A number of other equities analysts have also recently weighed in on the stock. Mizuho  reaffirmed a “buy” rating and set a $130.00 price target on shares of Merck & Co., Inc. in a research note on Monday, April 10th. Atlantic Securities boosted their price objective on shares of Merck & Co., Inc. from $122.00 to $127.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 7th. Morgan Stanley decreased their price objective on shares of Merck & Co., Inc. from $100.00 to $99.00 and set an “equal weight” rating on the stock in a research report on Friday, February 3rd. Credit Suisse Group upped their target price on shares of Merck & Co., Inc. from $125.00 to $126.00 and gave the company an “outperform” rating in a report on Tuesday, March 7th. Finally, Societe Generale lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Tuesday, March 28th. Seven analysts have rated the stock with a hold rating and seventeen have assigned  a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $120.65.

Shares of MRK opened at $114.83 on Monday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.23 and a current ratio of 1.47. The stock has a market capitalization of $291.51 billion, a P/E ratio of 20.11, a P/E/G ratio of 2.09 and a beta of 0.34. The company’s fifty day moving average is $108.50 and its two-hundred day moving average is $105.70. Merck & Co., Inc. has a 1 year low of $83.05 and a 1 year high of $116.44.

Merck & Co., Inc. (NYSE:MRK – Get Rating) last announced its quarterly earnings data on Thursday, February 2nd. The company reported $1.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.56 by $0.06. The company had revenue of $13.83 billion for the quarter, compared to analysts’ expectations of $13.66 billion. Merck & Co., Inc. had a net margin of 24.49% and a return on equity of 43.47%. Merck & Co., Inc.’s revenue was up 2.3% compared to the same quarter last year. During the same period in the previous year, the company posted $1.80 EPS.

The company also recently disclosed a quarterly dividend, which was paid on Monday, April 10th. Shareholders of record on Wednesday, March 15th were given a $0.73 dividend. This represents a $2.92 annualized dividend and a yield of 2.54%. The ex-dividend date  was Tuesday, March 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 51.14%.

In other news, EVP Steven Mizell sold 1,815 shares of the stock in a transaction that occurred on Monday, February 13th. The stock was sold at an average price of $109.10, for a total transaction of $198,016.50. Following the completion of the transaction, the executive vice president now directly owns 33,085 shares in the company, valued at approximately $3,609,573.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, EVP Steven Mizell sold 1,815 shares of the firm’s stock in a transaction on Monday, February 13th. The stock was sold at an average price of $109.10, for a total transaction of $198,016.50. Following the transaction, the executive vice president now directly owns 33,085 shares in the company, valued at $3,609,573.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Joseph Romanelli sold 5,000 shares of the firm’s stock in a transaction on Wednesday, February 15th. The stock was sold at an average price of $108.22, for a total value of $541,100.00. Following the transaction, the insider now owns 20,284 shares in the company, valued at $2,195,134.48. The disclosure for this sale can be found here. Insiders sold 150,306 shares of company stock valued at $17,162,278 over the last 90 days. 0.29% of the stock is owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in the stock. Retirement Financial Solutions LLC acquired a new position in shares of  Merck & Co., Inc. during the fourth quarter valued at $26,000.  Legend Financial Advisors Inc. purchased a new position in  Merck & Co., Inc. in the 3rd quarter worth about $27,000.  EdgeRock Capital LLC purchased a new position in  Merck & Co., Inc. in the 3rd quarter worth about $30,000.  Mach 1 Financial Group LLC purchased a new position in  Merck & Co., Inc. in the 3rd quarter worth about $30,000.  Finally, Tradewinds Capital Management LLC increased its stake in  Merck & Co., Inc. by 41.5% in the 4th quarter. Tradewinds Capital Management LLC now owns 317 shares of the company’s stock worth $35,000 after purchasing an additional 93 shares in the last quarter. 72.89% of the stock is currently owned by institutional investors.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.